NCT05918406View on ClinicalTrials.gov

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

August 18, 2023

Study Completion Date

August 18, 2023

Conditions
Dry EyeKeratoconjunctivitis Sicca
Interventions
COMBINATION_PRODUCT

Nasal Guide

Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID

Trial Locations (2)

08820

United States, New Jersey, Edison

07424

United States, New Jersey, Woodland Park

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT05918406 - Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya | Biotech Hunter | Biotech Hunter